We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.20 | 0.49% | 41.11 | 41.3125 | 40.87 | 40.95 | 2,730,464 | 01:00:00 |
From Apr 2019 to Apr 2024
By Tess Stynes
Five Prime Therapeutics Inc. (FPRX) said GlaxoSmithKline PLC (GSK, GSK.LN) exercised its option for an exclusive global license to products related to an undisclosed muscle-disease target discovered by the clinical-stage biotechnology company.
Five Prime shares were recently trading at $12.07, up 4.9%.
Five Prime will receive a payment of $1.5 million in connection with the option exercise and is eligible for as much as $122.5 million in milestone payments.
Five Prime and Glaxo began a collaboration in 2010 to discover and develop drug targets for skeletal muscle diseases using Five Prime's platform.
Write to Tess Stynes at tess.stynes@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
